NASDAQ · Drug Manufacturers - General · USD

Scilex Holding Company (SCLX) Stock Analysis

Scilex Holding Company (SCLX) is a Drug Manufacturers - General stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

SCLX

$2.56

+$0.03 (+1.19%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare SCLX with… →

SCLX Key Statistics

As of Oct 21, 2026

Trading

Open: $2.58
Previous Close: $2.53
Day's Range: 2.53–2.61
52-Week Range: 2.52–16.81
Volume: 25.88K
Beta: 1.79

Valuation

Market Cap: $18.01M
P/E Ratio: unprofitable
Forward P/E: 3.51
P/S ratio: 0.57
EPS (ttm): −49.70

Financials (FY)

Revenue (FY): $30.25M−46.54%
Net Income (FY): −$358.73M
Shares Outstanding: 7.03M
1-Year Return: −70.10%

Dividend and dates

Avg Volume: 49.00K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, SCLX closed at $2.56, −70.10% over 1 year.

Scilex Holding Company (SCLX) has a market capitalization of $18.01M.

In fiscal 2025, SCLX reported revenue of $30.25M.

SCLX Stock Return by Calendar Year

Scilex Holding Company (SCLX) return since Mar 2021: what $10,000 became

1 year: $10,000 $2,990; −70.10%
5 years: $10,000 $117; −98.83%
Since Mar 2021: $10,000 $119; −98.81%

If you had invested $10,000 in Scilex Holding Company (SCLX) at the close on March 5, 2021, the earliest close on record here, it would have been worth $119 at the close on October 21, 2026: −98.81% in total, −54.47% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

+1.93%−60.26%−48.87%−79.12%−18.18%−66.30%

2021*20222023202420252026*

Year	Return
2026 (partial year)	−66.30%
2025	−18.18%
2024	−79.12%
2023	−48.87%
2022	−60.26%
2021 (partial year)	+1.93%

As of October 21, 2026.

SCLX Revenue and Earnings by Fiscal Year

FY ends December

RevenueNet income

2022202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$30.25M	−$358.73M	−1,185.8%
2024	$56.59M	−$72.81M	−128.7%
2023	$46.74M	−$114.33M	−244.6%
2022	$38.03M	−$23.36M	−61.4%

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$30.25M	$19.65M	−$272.30M	−$358.73M	−1,185.8%
2024	$56.59M	$39.90M	−$92.79M	−$72.81M	−128.7%
2023	$46.74M	$31.06M	−$105.43M	−$114.33M	−244.6%
2022	$38.03M	$27.24M	−$50.63M	−$23.36M	−61.4%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

SCLX Valuation vs Drug Manufacturers - General Median

Median of 21 stocks

Metric	SCLX	Drug Manufacturers - General median	vs median
P/S ratio	0.57	3.23	0.2x the median

Medians across 21 Drug Manufacturers - General stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Analysis

Data-derived

Company Overview

Scilex Holding Company (SCLX) is capitalised at $18.01M on the latest close. It is classified in the Drug Manufacturers - General industry, within the Healthcare sector. The company reports 34 employees.

The most recent close on file for SCLX is $2.56, dated October 21, 2026. That is +$0.03 (+1.19%) against the previous close. Over the past 52 weeks the price has ranged from $2.52 to $16.81. The latest close sits 1.67% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $30.25M. That is −46.54% against the prior fiscal year, when revenue was $56.59M. The same year closed with a net loss of $358.73M. Trailing earnings per share are −49.7.

Across the 4 fiscal years on file, revenue moves from $38.03M in 2022 to $30.25M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. On forward earnings the ratio is 3.51. The price-to-sales ratio is 0.57. On price-to-sales that is 0.2 times the Drug Manufacturers - General median of 3.23. The medians here are taken across 21 Drug Manufacturers - General companies that report the metric.

Beta against the wider market is reported at 1.79. Daily returns over the trailing 5 years annualize to a volatility of 114.5%. The trailing one-year total return is −70.10%. Measured over 5 years, that is −58.90% a year compounded.

Growth & Income

The record shows no dividend for SCLX.

The strongest complete calendar year on file is 2025 at −18.18%; the weakest is 2024 at −79.12%. Of the 4 complete calendar years on file, 0 finished higher. 2026 is still running; the total return is −66.30% year to date.

Peer Comparison

Scilex Holding Company (SCLX) operates in the Drug Manufacturers - General industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
Scilex Holding Company	SCLX	$18.01M	—
Eli Lilly and Company	LLY	$1.13T	42.7
Johnson & Johnson	JNJ	$621.22B	39.1
AbbVie Inc.	ABBV	$503.27B	80.5

The Drug Manufacturers - General industry average P/E ratio is 25.2x. Scilex Holding Company has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Drug Manufacturers - General Stocks

LLY

Eli Lilly and Company

$1.13T

JNJ

Johnson & Johnson

$621.22B

ABBV

AbbVie Inc.

$503.27B

MRK

Merck & Co., Inc.

$369.78B

NVS

Novartis AG

$292.58B

AZN

AstraZeneca PLC

$261.82B

View all Drug Manufacturers - General stocks →

Popular Healthcare Stocks

UNH

UnitedHealth Group Incorporated

$374.30B

TMO

Thermo Fisher Scientific Inc.

$256.61B

AMGN

Amgen Inc.

$236.98B

GILD

Gilead Sciences, Inc.

$190.42B

ABT

Abbott Laboratories

$173.92B

View all Healthcare stocks →

About Scilex Holding Company

Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company also develops three product candidates, including SP-102 (10 mg, dexamethasone sodium phosphate viscous gel - SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4%, a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules), a novel low-dose delayed-release naltrexone hydrochloride, which has completed phase 1 trials for the treatment of fibromyalgia. It has an agreement with Oishi and Itochu to develop lidocaine tape products, including ZTlido and SP-103; Lifecore Biomedical, LLC for clinical trial material manufacturing and development services for SEMDEXA; and Tulex Master, which develops, tests, and manufactures clinical supplies of SP-104. Scilex Holding Company is based in Palo Alto, California.

Visit website →